Maximillian Greenwald
About
Research
Publications
2024
A Computational Account of the Development and Evolution of Psychotic Symptoms.
Powers A, Angelos P, Bond A, Farina E, Fredericks C, Gandhi J, Greenwald M, Hernandez-Busot G, Hosein G, Kelley M, Mourgues C, Palmer W, Rodriguez-Sanchez J, Seabury R, Toribio S, Vin R, Weleff J, Woods S, Benrimoh D. A Computational Account of the Development and Evolution of Psychotic Symptoms. Biological Psychiatry 2024 PMID: 39260466, DOI: 10.1016/j.biopsych.2024.08.026.Peer-Reviewed Original ResearchPsychotic symptomsSymptom formationEmergence of psychotic symptomsConversion to psychosisPrediction error signalsIncoming sensory informationHallucination severityDiminished signal-to-noise ratioComputational accountPsychiatric interventionNeural systemsHallucinationsIncreasing convictionOver-reliancePsychosisSensory informationLongitudinal developmentSymptomsBelief formation
2023
Inflammation, stress and depression: An exploration of ketamine’s therapeutic profile
Johnston J, Greenwald M, Henter I, Kraus C, Mkrtchian A, Clark N, Park L, Gold P, Zarate C, Kadriu B. Inflammation, stress and depression: An exploration of ketamine’s therapeutic profile. Drug Discovery Today 2023, 28: 103518. PMID: 36758932, PMCID: PMC10050119, DOI: 10.1016/j.drudis.2023.103518.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsUnique therapeutic mechanismTherapeutic profileCentral nervous system inflammationHypothalamic pituitary adrenal axisNervous system inflammationRapid-acting antidepressantsTreatment-resistant depressionAnti-inflammatory actionPeripheral inflammatory biomarkersSystem inflammationInflammatory biomarkersProinflammatory stateCytokine suppressionAdrenal axisKynurenine pathwayTherapeutic effectTherapeutic mechanismAnimal modelsInflammationDepressionAntidepressantsKetamineFurther investigationBiomarkers
2022
Perceptual pathways to hallucinogenesis
Sheldon AD, Kafadar E, Fisher V, Greenwald MS, Aitken F, Negreira AM, Woods SW, Powers AR. Perceptual pathways to hallucinogenesis. Schizophrenia Research 2022, 245: 77-89. PMID: 35216865, PMCID: PMC9232894, DOI: 10.1016/j.schres.2022.02.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements
2021
Reply to: “Letter to the Editor: Are ketamine-induced subjective bodily experiences associated with antidepressant effects? A sensation of floating and a sensation of Lightnessare not the same – A comment on Acevedo-Diaz et al.” (Jpsychiatrres-D-21-00121)
Acevedo-Diaz EE, Greenwald M, Cavanaugh GW, Greenstein DK, Kraus C, Kadriu B, Zarate CA, Park LT. Reply to: “Letter to the Editor: Are ketamine-induced subjective bodily experiences associated with antidepressant effects? A sensation of floating and a sensation of Lightnessare not the same – A comment on Acevedo-Diaz et al.” (Jpsychiatrres-D-21-00121). Journal Of Psychiatric Research 2021, 137: 409-410. PMID: 33773443, PMCID: PMC8223260, DOI: 10.1016/j.jpsychires.2021.03.018.Commentaries, Editorials and Letters
2020
Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants
Kadriu B, Greenwald M, Henter ID, Gilbert JR, Kraus C, Park LT, Zarate CA. Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants. The International Journal Of Neuropsychopharmacology 2020, 24: 8-21. PMID: 33252694, PMCID: PMC7816692, DOI: 10.1093/ijnp/pyaa087.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKetamine researchSerotonergic psychedelicsAntidepressant effectsAntidepressant efficacyRapid-acting antidepressantsRapid acting antidepressantsGlutamatergic modulator ketamineCortical network activityDownstream pharmacological effectsActivity-dependent mannerAcute alterationsTherapeutic responseNeuroplastic effectsGlutamatergic pathwaysPharmacological effectsKetaminePsychoactive componentTherapeutic relevanceAntidepressantsDownstream mechanismsPsychoactive effectsMolecular effectsNetwork activityCommon mechanismEfficacy